Pegah Mehrpouya-Bahrami

Critic
DISC Type : C

Associate Director Immunology and CGT Biomarkers, Medical & Scientific Affairs at Labcorp Drug Development

Indianapolis, Indiana, United States

Overview

Pegah Mehrpouya-Bahrami is the Associate Director and Immunology Therapeutic Area Lead at Labcorp. She leads teams to deliver biomarker solutions for drug development, specializing in cell and gene therapy, immunology, and precision medicine. She holds a Ph. D. in Biomedical Science from the University of South Carolina and has studied Strategy Execution at Harvard Business School.

Her doctoral research focused on the regulation of inflammatory diseases by microRNA and microbiota, specifically investigating cannabinoid receptors as therapeutic targets.

Personality Overview

Information Seeker

Precise

Negotiator

They are quite likely to negotiate on pricing or other key terms.  They prefer to do logical analysis and value evidence over emotions. They don’t appreciate bells and whistles unless backed by data.

Topics They Care About

Cell & Gene Therapy
As the CGT Therapeutic Area Lead at Labcorp, she is at the forefront of developing and leading strategies for cell and gene therapy biomarkers in clinical trials.
Biomarker Solutions
Her role is centered around leading multidisciplinary teams to create and execute biomarker solutions for drug development, from discovery to validation.
Autoimmune Diseases
She recently shared a white paper on utilizing cell therapy to move beyond symptom control toward immune reprogramming for autoimmune diseases.

Media Appearances

Pegah has no verified media appearances

Work History

7-2023
Associate Director Immunology and CGT Biomarkers, Medical & Scientific Affairs at Labcorp Drug Development
2-2022 - 7-2023
Manager of Central laboratory services and Translational Biomarker Solutions( Flow Cytometry) at Labcorp Drug Development
5-2019 - 3-2022
mass cytometry (cyTOF)Staff Scientist, Translational Biomarker Solutions at Labcorp Drug Development
8-2016 - 5-2019
Postdoctoral Fellow at Indiana University–Purdue University Indianapolis
8-2010 - 8-2016
Ph.D. and Graduate Research Assistant at University of South Carolina

Education

2021 - 2021
Strategy Execution from Harvard Business School
2010 - 2016
Doctor of Philosophy (Ph.D.) from University of South Carolina

More Information

Social Presence :

Prographics :

Exp : 19 Location : Indianapolis, Indiana, United States Job Level : Mid-senior Designation : Associate Director Immunology and CGT Biomarkers, Medical & Scientific Affairs at Labcorp Drug Development
URL has been copied!

Insights For Selling To Pegah

During A Call Or A Meeting

DO's

  • Don’t forget to mention how you compare to competition on both features and pricing
  • Keep some extra margin while sharing pricing, they are likely to negotiate later
  • Be formal and objective, they will appreciate it more

DONT's

  • Don’t try to give too many examples of other users, they like to make their own decisions
  • Avoid pushing them too much to involve other stakeholders unless it is critical
  • Do not use very emotional or colorful language

When Cold Calling

When Writing An Email

While Negotiating & Closing

    The secret to closing fast with Pegah is

  • Strong evidence of ROI, effective pricing, and proven data points matter the most to them.
  • Will you ever get a clear answer from Pegah

  • It is not very hard for them to say no if they are not convinced about the decision.

Insights For Deal Planning

    How fast (or slow) will Pegah move?

  • They are neither the fastest nor the slowest decision makers, they are somewhere in the middle.
  • Can Pegah take some risk or not?

  • They can bear some risk if their analysis backs the decision.

You And Pegah

Personality Compatibility


Other Labcorp Drug Development Employees

Explore more public profiles from related professionals at the same organization.

More Profiles

Discover additional public profiles from our index.

Search more profiles

Looking for someone else? Search here for anyone.

Or visit Humantic AI to know more.